BioMarin Pharmaceutical (BMRN) is back in focus after the FDA approved a supplemental Biologics License Application for PALYNZIQ, expanding treatment eligibility to pediatric phenylketonuria patients aged 12 and older.

The PALYNZIQ approval lands after a stretch where BioMarin’s share price has shown improving momentum, with a 13.73% 90 day share price return and a 5.14% 30 day share price return, even though the 1 year total shareholder return is a 15.15% decline.

If you are watching how drug approvals can reframe growth stories, it could be a good time to broaden your search and check out 32 healthcare AI stocks through our screener.

With shares up over the past quarter but still carrying a 1 year total return decline, and trading at a sizable intrinsic discount estimate, you have to ask: is BioMarin still on sale, or is the market already baking in future growth?

Most Popular Narrative: 31.1% Undervalued

With BioMarin Pharmaceutical closing at $61.12 against a most-followed fair value estimate of about $88.65, the current setup centers on how long term growth and profitability assumptions stack up against that gap.

Operational efficiency, disciplined cost management, and regulatory advantages support sustained profitability and long-term margin stability.

Revenue and earnings face mounting risks from escalating competition, pricing pressures, pipeline dependency, heightened expenses, and regulatory uncertainty across key products and markets.

Curious what earnings power is baked into that valuation gap? The narrative leans on rising margins, steady revenue expansion, and a richer future earnings multiple. The exact mix of those levers might surprise you.

Result: Fair Value of $88.65 (UNDERVALUED)

However, you still need to keep an eye on risks such as heavier competition in rare disease treatments and rising R&D or SG&A spending that could squeeze margins.

Another Way To Look At Valuation

Our fair value work portrays BioMarin as heavily undervalued, yet the current P/E of 33.7x tells a different story. That is richer than the US biotech average at 21x, the peer average at 20.1x, and even the fair ratio estimate of 26.4x. This raises the question of whether this represents a margin-of-safety opportunity or a valuation trap.

Next Steps

Mixed signals on BioMarin after all this? If you want to move quickly and reach your own view, it is worth weighing the company’s 2 key rewards and 2 important warning signs before deciding what this latest move means for you.

Looking for more investment ideas?

If this news has you rethinking your watchlist, do not stop at one company. Broader idea hunting can reveal opportunities that fit your goals far better.

• Spot potential value candidates early by scanning our 49 high quality undervalued stocks, sourced from companies that pair fundamentals with appealing pricing signals.
• Prioritize strength and resilience by focusing on businesses in the solid balance sheet and fundamentals stocks screener (41 results), which aim for healthier financial foundations.
• Hunt for less crowded opportunities with the screener containing 24 high quality undiscovered gems, where quieter names may still offer compelling fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.